On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
TuesdayDec 12, 2017 9:29 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Inks LOI to Acquire Outstanding Shares of Harvest Medicine Inc.

Abcann Global (TSX.V: ABCN) (OTCQB: ABCCF) this morning said that the company recently entered into a binding Letter of Intent (“LOI”) dated December 11, 2017 to acquire all outstanding securities of Canada’s fastest growing medical cannabis clinic, Harvest Medicine Inc. Per the terms of the agreement, Abcann will make a $1,500,000 cash payment and issue 1,056,338 common shares in the capital of ABcann valued at $1,500,000, based on a deemed price of $1.42 per share. Upon the closing of the transaction, Harvest Medicine founder and CEO, Shekhar Parmar, is anticipated to join ABcann’s executive team as Chief Strategy Officer and…

Continue Reading

MondayDec 11, 2017 5:16 pm

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Develops Cannabis-Based Therapeutics in Response to Opioid Epidemic

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is using scientific research and development to stake out its spot in the medical marijuana industry. An article discussing this reads: “Veritas Pharma’s mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company’s approach, combined with its strategic alliances, will effectively address the medical community’s concerns over the complexities of cannabis potency, efficacy, quality and content in the…

Continue Reading

MondayDec 11, 2017 3:53 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Utilizes Proprietary Advanced Biosynthesis Process to Develop Cannabinoids-based Therapies

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) remains focused on discovering potential breakthrough cannabinoid-based therapies by utilizing its proprietary cannabinoid biosynthesis process and its bioinformatics drug and disease targeting tool. An article discussing this reads: “Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact…

Continue Reading

MondayDec 11, 2017 3:39 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids…

Continue Reading

MondayDec 11, 2017 9:33 am

CannabisNewsBreaks – EVIO, Inc. (EVIO) Signs Non-Binding LOI to Acquire Licensed Cannabis Laboratory in Berkeley, CA

EVIO (OTCQB: EVIO) this morning announced that it has signed a non-binding Letter of Intent (“LOI”) to acquire 60% of C3 Labs, LLC. C3 Labs is located in Berkeley, CA, which accelerates the company’s intent to expand into Northern California prior to the anticipated increase in demand for analytical testing services. Subject to customary closing conditions, the transaction is expected to close in the first quarter of 2018. “C3 Labs been serving the cannabis industry for years, providing product formulation, research and development services that aligns with EVIO’s longer term strategy to expand our scope of services. We are working…

Continue Reading

FridayDec 08, 2017 12:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

Continue Reading

FridayDec 08, 2017 12:41 pm

CannabisNewsBreaks – Skinvisible, Inc. (SKVI) Poised for Growth More than Skin Deep

Skinvisible (OTCQB: SKVI) is poised for growth in the booming global topical drug delivery market. A recent article highlights the company’s positioning, stating, “The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good…

Continue Reading

FridayDec 08, 2017 12:14 pm

CannabisNewsBreaks – Grey Cloak Tech Inc. (GRCK) Targets Massive CBD Market Through Eqova Life Sciences Subsidiary

Grey Cloak Tech (OTCQB: GRCK) is positioning itself to profit from the growing cannabinoid (“CBD”) market through its wholly owned subsidiary Eqova Life Sciences. An article discussing this reads: “Eqova Life Sciences recently exhibited the company’s CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company’s formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care…

Continue Reading

FridayDec 08, 2017 9:13 am

CannabisNewsBreaks – SeeThruEquity Updates Coverage on PotNetwork Holding, Inc. (POTN)

SeeThruEquity recently issued a company update and price target of $0.40 on shares of PotNetwork Holding, Inc.’s (OTC: POTN) stock. SeeThruEquity increased the price target for PotNetwork based on encouraging results since it initiated coverage of the holding company, such as top line growth and reduction in shares outstanding. New product launches, aggressive marketing initiatives and entry into to new markets were noted by the analyst as upcoming catalysts for the company. To view the full press release, visit http://cnw.fm/mzlK3 About PotNetwork Holding, Inc. PotNetwork Holding, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company…

Continue Reading

FridayDec 08, 2017 8:31 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Retains Medical Director to Advise Cannabis Research Programs

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director. Alexander’s role will be to confirm the medical integrity of cannabis research programs conducted by the company’s subsidiary, Cannevert Therapeutics Ltd. In addition, Alexander will develop a medical affairs strategy to support cannabis strains currently in development. “Dr. Alexander brings a wealth of medical knowledge, a clear understanding of current clinical practice and regulatory needs, and a pledge to educate all stakeholders about therapeutic strains that are based on Cannevert’s experimental evidence,” Veritas CEO Dr. Lui…

Continue Reading

Official NewsWire Relationships

Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722